BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6253346)

  • 1. Lymphoproliferative response to membrane extracts of nasopharyngeal carcinoma.
    Tsukuda M; Sawaki S; Yanoma S; Yoshimura N; Takei M; Takada M; Kawamura A
    Gan; 1980 Aug; 71(4):441-50. PubMed ID: 6253346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.
    Liu MY; Huang YT; Sheen TS; Chen JY; Tsai CH
    J Med Virol; 2004 Aug; 73(4):574-82. PubMed ID: 15221902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
    Gunvén P; Klein G; Henle W; Henle G; Forsby N
    Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-related lymphocyte stimulation inhibitor: a possible prognostic tool for undifferentiated nasopharyngeal carcinoma.
    Kamaraju LS; Levine PH; Sundar SK; Ablashi DV; Faggioni A; Armstrong GR; Bertram G; Krueger GR
    J Natl Cancer Inst; 1983 Apr; 70(4):643-7. PubMed ID: 6300502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating immune complexes in patients with nasopharyngeal carcinoma.
    Wolf GT; Wolfe RA
    Laryngoscope; 1990 Mar; 100(3):302-8. PubMed ID: 1689798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serologic diagnosis of nasopharyngeal carcinoma. A double-blind study of four EB virus antibodies with evaluation by sequential discrimination.
    Cai WM; Li YW; Wu B; Liu YY; Hu YH; Gu XZ; Liu HY; Wang GD
    Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1763-8. PubMed ID: 6319338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
    Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
    J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological types of nasopharyngeal carcinoma as compared to EBV serology.
    Krueger GR; Kottaridis SD; Wolf H; Ablashi DV; Sesterhenn K; Bertram G
    Anticancer Res; 1981; 1(4):187-94. PubMed ID: 6285799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
    Mazeron MC
    Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.